Prospective Study
Copyright ©The Author(s) 2021.
World J Crit Care Med. Jan 9, 2021; 10(1): 22-34
Published online Jan 9, 2021. doi: 10.5492/wjccm.v10.i1.22
Table 1 Baseline characteristics of all the patients before initiating the therapy
Baseline characteristics
Findings, mean ± SD
Age, yr47.46 ± 15.56
Heart rate, beats/min117 ± 22.05
MAP, mmHg69.15 ± 9.19
GCS9.04 ± 3.06
APACHE-II25.46 ± 5.06
SOFA12.90 ± 4.37
Leucocytes, µL15311.44 ± 7140.54
Platelets, cells/mm3139153.48 ± 89467.72
S. Creatinine, mg/dL2.74 ± 1.72
S. Lactate, mmoL/L4.61 ± 2.87
PaCO243.37 ± 18.22
PaO294.02 ± 49.09
FiO248.78 ± 43.28
PaO2/FiO2118.6 ± 58.01
APACHE II: Acute physiology and chronic health evaluation; FiO2: Fraction of inspiration O2; GCS: Glasgow coma scale; MAP: Mean arterial pressure; SD: Standard deviation; SOFA: Sequential organ failure assessment; PaCO2: Partial pressure of carbon dioxide; PaO2: Alveolar oxygen partial pressure.
Table 2 Percentage decrease in patients and vasopressor doses (survivors)
Vasopressor drug, µg/kg/min
Pre CytoSorb®, therapy patient number (n), dose (median)
Post CytoSorb® Therapy, patient number (n), dose (median)
% Decrease in dose
P value (dose)
Norepinephrine21; 118; 0.4543.30.160
Epinephrine4; 0.0551; 0.05564.4-
Vasopressin9; 1.57; 115.40.816
Table 3 Change in laboratory parameters for survivors
Parameters
Pre CytoSorb® therapy
Post CytoSorb® therapy
P value
Hb, g/dL10.01 ± 2.209.28 ± 1.530.1830
HCT, %29.74 ± 8.425.75 ± 7.670.0909
Leucocytes, µL16724 ± 542511215 ± 33170.00011
Platelets, cells/mm3139256 ± 88029181203 ± 1813810.2938
S. Creatinine, mg/dL3.13 ± 1.922.08 ± 1.020.01901
S. Lactate, mmol/L4.75 ± 2.772.88 ± 2.390.01201
SGOT, U/L488.44 ± 1570.42369.95 ± 1134.740.7661
SGPT, U/L192.72 ± 298.99145.90 ± 236.970.5503
BUN, mg/dL76.21 ± 61.8862.39 ± 52.280.4076
Bilirubin, mg/dL9.91 ± 36.778.35 ± 31.360.8730
Sodium, mmol/L134.38 ± 25.69134.32 ± 6.200.9908
Potassium, mmol/L3.98 ± 0.953.73 ± 1.050.3723
Albumin, g/L2.65 ± 0.932.71 ± 0.950.8261
Arterial pH7.35 ± 0.1007.36 ± 0.1050.7291
Bicarbonate24.89 ± 10.7124.75 ± 9.210.9599
1Significant value P < 0.05, all values are defined as mean ± SD.
BUN: Blood urea nitrogen; Hb: Hemoglobin; HCT: Hematocrit; SD: Standard deviation; SGOT: Serum glutamic oxaloacetic transaminase; SGPT: Serum glutamic-pyruvic transaminase.
Table 4 Cytokine assay results for survivors
Cytokine
Pre CytoSorb® therapy, mean ± SD
Post CytoSorb® therapy, mean ± SD
Percentage change
P value
IL1, pg/mL10.74 ± 9.709.54 ± 9.6611.110.5580
IL6, pg/mL889.15 ± 1307.43423.69 ± 1105.5552.340.0792
IL: Interleukin.
Table 5 Change in vital parameters in survivors
Parameters
Survivor group
P value
Pre CytoSorb® therapy, mean ± SD
Post CytoSorb® therapy, mean ± SD
Heart rate, beats/min118.57 ± 19.8103.07 ± 19.380.00651
MAP, mmHg68.61 ± 9.6279.42 ± 9.050.00011
GCS9.86 ± 2.3412.20 ± 1.470.00011
PaCO243.32 ± 18.6338.57 ± 11.660.2757
PaO2/FiO2162.09 ± 82.99161.20 ± 66.580.9704
1Significant P value < 0.05.
All values are defined as mean ± SD. FiO2: Fraction of inspiration O2; GCS: Glasgow coma scale; MAP: Mean arterial pressure; PaCO2: Partial pressure of carbon dioxide; PaO2: Alveolar oxygen partial pressure; SD: Standard deviation.